Liver Specialist: How to Detect & Reverse Fatty Liver Disease Before It’s Too Late | Aleksander Krag

Episode Overview

• Host Simon Hill (Nutritionist, Physiotherapist, Author, and Podcast Host) interviews Aleksander Krag, MD, PhD—Professor of Hepatology, Director of the Odense Liver Research Centre at the University of Southern Denmark and Odense University Hospital, 2023 President of the European Association for the Study of the Liver (EASL), and co-author of The Lancet seminar and commission on liver disease—on how to detect, prevent, and reverse steatotic liver disease before it silently progresses to cirrhosis and liver failure.
• Approximately 30% of the global population has steatotic liver disease, which remains asymptomatic for 15 to 20 years until advanced stages present with severe complications like ascites, vomiting blood, hepatic encephalopathy, or liver cancer.
• The conversation traces the 2023 shift in medical nomenclature away from stigmatizing terms like "fatty" and "alcoholic," reveals massive underreporting of alcohol intake uncovered by objective blood biomarkers, and explains the biology of liver fat accumulation and scarring.
• Krag details targeted diagnostic strategies (such as waist circumference, FIB-4, and FibroScan), lifestyle interventions, and newly approved pharmacological breakthroughs like resmetirom and semaglutide that prove liver fibrosis—and potentially even cirrhosis—can be reversed.
• Disclosures: Episode sponsors include Eight Sleep (promo code THEPROOF for up to $350 off), IM8 Health (Hill sits on IM8's scientific advisory board; promo code SIMON for 10% off first order plus a free welcome kit), Momentous (promo code THEPROOF for up to 35% off first order), and Swimclub (promo code THEPROOF for 25% off first order). Krag discloses no personal financial conflicts, noting that while some publications discussed are associated with pharmaceutical companies, others are not.

Key Concepts

• The Silent Progression and Systemic Role of the Liver: Driven by the memory of a patient named "Henry" (a man around 50–55 years old who was sick in his liver for 15–20 years without knowing it, presented with advanced-stage liver disease and cancer, was too sick for a transplant, and died), Krag aims to find patients 15 years earlier to give them 20–30 more years of life. The liver generates most blood proteins, cleans blood from the gut, and acts as a metabolic supercomputer (handling processes like gluconeogenesis). When liver capacity is lost in advanced stages, the body digests itself, leading to muscle mass loss (sarcopenia), portal hypertension, esophageal varices, kidney issues, and brain affection (hepatic encephalopathy).
• Cardiovascular Overlap and the Simple Steatosis Debate: Steatotic liver disease overlaps heavily with type 2 diabetes and obesity and is strongly associated with cardiovascular disease and strokes due to shared risk factors (hypertension, dyslipidemia, hypercholesterolemia, diabetes, obesity) and systemic low-grade inflammation. However, Krag notes it is still under debate whether simple steatosis (liver fat alone without fibrosis) is an independent additional risk factor for cardiovascular disease, and he has authored a paper arguing against overselling fat alone to avoid unnecessarily scaring patients.
• The 2023 Nomenclature Shift and Alcohol Subtypes: In 2023, global liver societies replaced "non-alcoholic fatty liver disease" (NAFLD) with Steatotic Liver Disease (SLD)—defined as having >5% fat in the liver (via ultrasound, CT, biopsy, or FibroScan) plus at least one cardiometabolic risk factor—to eliminate the stigma of the words "fatty" and "alcoholic." Accounting for regional unit differences (1 unit = 12 grams of alcohol in the US; 10 grams in Europe), SLD is divided into three subtypes:
• MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease): <20 grams/day of alcohol for women, <30 grams/day for men.
• MetALD (Metabolic Dysfunction and Alcohol-Associated): 20–50 grams/day for women, 30–60 grams/day for men.
• ALD (Alcohol-Associated Liver Disease): >50 grams/day for women, >60 grams/day for men (using "alcohol-associated" rather than "alcoholic").
• Hidden Alcohol Consumption Revealed by PEth Testing: Based on alcohol sales data, the average American and European drinks more than 2 units a day (even accounting for the 10–20% of the population that abstains). When red blood cell membranes (phospholipids) are exposed to alcohol, they form phosphatidylethanol (PEth), measurable via liquid chromatography-mass spectrometry. While a US colleague's cohort of "100% sure" MASLD patients showed 10% had high PEth levels, Krag's cohort of 3,000 people in Odense, Denmark, revealed that 30% to 38% of patients categorized as MASLD actually had PEth levels belonging in the MetALD or ALD groups, and >50% of the MetALD group belonged in the ALD group—proving self-reported databases like NHANES and the UK Biobank significantly underestimate alcohol's role.
• Alcohol Toxicity, Sex Differences, and Metabolic Synergy: At a population level, the relationship between alcohol intake and advanced liver disease risk is roughly linear, and the WHO states there is no safe limit for alcohol consumption. While linear for males, the risk curve steepens for females because alcohol is much more toxic to women. Combining high alcohol consumption with type 2 diabetes increases liver disease risk by 3 to 5 times compared to a lean individual. Alcohol damages the liver through three mechanisms: excess calories metabolized into triglycerides, toxic breakdown into acetaldehyde causing inflammation, and gut microbiome alterations ("leaky gut") that allow DAMPs and PAMPs (damage- and pathogen-associated molecular patterns) to enter the liver and drive fibrosis.
• Origins of Liver Fat, Genetics, and Fibrosis Timelines: Everything absorbed from the gut travels directly to the liver. During continuous energy imbalance or insulin resistance, the liver holds back fat internally to protect the bloodstream from floating fat before trafficking it to adipocytes. Fibrosis is graded in stages 0, 1, 2, 3, and 4 (cirrhosis). Progressing one stage takes ~7 years on average in MASLD, but adding alcohol accelerates progression to ~3 years per stage. Advanced disease typically presents around age 50 for alcohol-associated disease and slightly older for MASLD, though rare rapid progressors present in their late 20s or 30s. Genetically, PNPLA3 is the most important risk variant for both alcohol and non-alcohol SLD, while protective genes linked to lipid metabolism are targets for drugs in development. Using lipidomics (measuring 1,000 blood lipids), Krag's team found that specific lipids disappear as liver disease progresses, correlating with decompensation and mortality.
• Lifestyle Nuances (Smoking, Coffee, Fructose, and Diet Trials): Tobacco smoking is directly and independently associated with liver fibrosis and cancer, though Krag notes he cannot explain the specific mechanism for how smoking causes fibrosis. Conversely, 20–30 years of data show coffee (especially filter coffee over espresso) is associated with less liver fat and better outcomes, though Krag candidly admits he does not know whether the mechanism stems from caffeine, polyphenols, or another compound. Regarding fructose, Krag cautions against eating "a ton of fruit every day" because fructose converts to triglycerides in the liver, but clarifies upon pushback from Hill that this is only an issue during energy excess/imbalance, not in active, metabolically healthy individuals. In a randomized study by Krag's team comparing a low-carb, high-fat (LCHF) diet against a standard diabetes diet, the LCHF diet reduced liver fat and improved glycemic control, though patients reverted to old habits once dietitian follow-up ended. Krag also notes he is "not completely sure" how compelling the evidence is that saturated fat acts differently on the liver than unsaturated fat independent of calories.
• Diagnostic Pathways and Targeted vs. Population Screening: Simple blood tests cannot detect steatosis or inflammation, and having normal HbA1c, triglycerides, blood pressure, ApoB, waist circumference, and liver function tests while having fibrosis is rare (occurring only in "lean MASH" or very young heavy drinkers). Guidelines recommend screening with the FIB-4 index (calculated from age, AST, ALT, and platelets), followed by confirmatory ELF (Enhanced Liver Fibrosis) blood testing or elastography (FibroScan, ultrasound, or MRI elastography) to measure tissue stiffness. In a Lancet study screening 3,500 people in Europe, Krag's team found no evidence for general population screening due to low prevalence of advanced fibrosis; instead, screening should target individuals with type 2 diabetes, Grade 3 obesity, or stacked risk factors.
• Liver Regeneration, Recompensation, and Breakthrough Therapeutics: Unlike a finger or a kidney, a normal liver grows back completely if a chunk is surgically removed. Historically viewed as static and permanent, scar tissue (extracellular matrix/collagen filaments) is actually active and reversible in Hepatitis B, Hepatitis C, and SLD—even up to decompensated cirrhosis ("recompensation" upon removing the root cause), though the exact point of no return when collagen cross-linking becomes irreversible remains incompletely understood. After a 20-year search, the FDA and EMA conditionally approved the first two drugs for MASH with significant fibrosis (to be used alongside diet and exercise) following positive Phase 3 trials:
• Semaglutide (Wegovy, Novo Nordisk): Although hepatocytes lack GLP-1 receptors, recent publications (including work by Daniel Drucker) identified receptors in sinusoidal endothelial cells. After "wishy" fibrosis results in Phase 2, a Phase 3 trial (~1,000 people treated for 72 weeks) demonstrated significant fibrosis reduction.
• Resmetirom (Rezdiffra): MASH patients experience localized hypothyroidism in the liver; resmetirom targets the liver to reverse this local hypothyroidism, exerting an anti-fibrotic effect and improving lipids without altering body weight or glycemic control.
• FGF21 Analogues & Brain Reward Pathways: Fibroblast growth factor 21 analogues are entering Phase 3 trials; Phase 2 signals show reversal of cirrhosis, though Krag cautions "we have to be a little bit careful" until Phase 3 data arrives. Furthermore, both GLP-1s and FGF21s (depending on molecule size) cross the blood-brain barrier to affect the brain's reward system and reduce alcohol intake, with a trial of semaglutide for alcohol-related liver disease set to be presented at the November Liver Meeting.
• Public Health Policy Levers: Because steatotic liver diseases are 100% preventable in theory, the EASL-Lancet Commission mapped how many deaths could be prevented through policy measures: raising alcohol prices, restricting alcohol and unhealthy food marketing to children, raising legal drinking ages (currently 16 years old in Denmark), and removing VAT on vegetables.

Quotes

• At 0:00:00 - "These diseases that kill so many people are 100% preventable. It's associated with our behavior. Nobody choose to drink 20 units a day. Nobody choose to have a BMI of 40. They wished a different life." - Krag framing steatotic liver disease as a preventable condition rooted in environment and behavior rather than personal moral failure.
• At 0:04:50 - "Liver disease until very advanced stages is asymptomatic. So the issue is as many of these people, they have no idea." - Krag explaining why patients frequently progress for 15 to 20 years without diagnosis until life-threatening complications appear.
• At 0:07:20 - "As many of the other beliefs we've had and sort of truths, they turn out to be wrong. Fibrosis tissue, scarring tissue, in many, a very active tissue, and that actually mean that it actually can be reversed." - Krag overturning decades of medical dogma that taught liver scarring was static and permanent.
• At 0:08:34 - "Sometimes when they do surgery, you cut out a chunk of the liver, and if it's otherwise a normal liver, it grows out again. It's not happening like that with a finger, or if you lose a kidney, it doesn't grow out. So the liver is unique in the body in that sense." - Krag illustrating the extraordinary regenerative capacity of healthy liver tissue.
• At 0:13:20 - "Because 'fatty' in most language is basically a stigmatizing word. And then it hold 'fatty' and 'non-alcoholic.' And it's also weird to have, you have a disease, and we start to say what it's not." - Krag detailing the rationale behind the 2023 global consensus to rename NAFLD to Steatotic Liver Disease (SLD).
• At 0:15:15 - "Alcohol is basically the same as MASLD, just with, let's say, oil in the fire." - Krag describing how alcohol accelerates metabolic liver damage, cutting the average time per fibrosis stage from ~7 years down to ~3 years.
• At 0:20:40 - "We have in our own cohort, a bigger cohort with 3,000 people here in Denmark, in Odense, measured that up to 30%, or actually 38% of those in the MASLD category have this elevated to a level where they actually belong in the MetALD or ALD group." - Krag sharing objective PEth blood test data demonstrating widespread underreporting of alcohol consumption among patients diagnosed with metabolic liver disease.
• At 0:23:35 - "If you should ask WHO, they say there's no safe limit for alcohol consumption." - Krag discussing the linear population risk curve between alcohol intake and advanced liver disease.
• At 0:34:35 - "Because you cannot have a circulation which that's floating with fat. So the liver is actually trying to protect the body with holding back the fat, accumulating it in the liver." - Krag explaining the physiological reason the liver stores excess energy as internal triglycerides during insulin resistance and calorie surplus.
• At 0:41:23 - "Remember that fruit, what is it that made a fruit lovely? That is fructose. And how is fructose broken down? That is made into fat, triglycerides in the liver. So that's again, don't eat a ton of fruit every day because it's definitely not good for your liver and you don't need all that." - Krag cautioning against excessive fructose consumption, which he clarifies applies to individuals in an overall energy surplus rather than active, metabolically healthy people.
• At 0:47:49 - "If you should choose one very simple parameter to risk assess, then start with the abdominal perimeter." - Krag identifying waist circumference as the single best at-home metric for assessing liver disease risk based on a study of 5,000 people.
• At 0:50:32 - "That sort of measure the stiffness of the tissue. Originally, it was developed to measure stiffness of a cheese in France, if it was mature or not." - Krag sharing the origin story of FibroScan elastography technology, now the clinical standard for non-invasively measuring liver scarring.
• At 1:22:15 - "When you go for your general practitioner and you anyway have checkup for your type 2 diabetes or your obesity, ask for the liver. Ask for a FIB-4." - Krag providing a direct, actionable step for at-risk patients to catch silent liver fibrosis during routine medical visits.

Takeaways

• Measure your waist circumference at home: Based on a study of 5,000 people, abdominal perimeter is the single best clinical parameter to self-assess your risk for visceral obesity and steatotic liver disease (using race-adjusted thresholds, such as lower cutoffs for Asian populations compared to Caucasian populations).
• Request a FIB-4 calculation from your doctor: If you have type 2 diabetes, obesity, or multiple cardiometabolic risk factors, do not rely on standard liver enzyme tests alone; ask your general practitioner to calculate your FIB-4 score (using age, AST, ALT, and platelets) and follow up with an ELF blood test or elastography (FibroScan) if elevated.
• Audit your true alcohol intake and schedule alcohol-free days: Recognize that self-assessments often underestimate alcohol intake and that consuming 12–20 drinks per week drives silent fibrosis—especially in women and individuals with type 2 diabetes, where alcohol multiplies liver disease risk by 3 to 5 times. Give your liver regular alcohol-free days and reduce total weekly volume.
• Prioritize sustainable energy balance over dogmatic macronutrient ratios: Whether using a Mediterranean diet, calorie restriction, or a low-carb, high-fat approach, choose a dietary pattern you can adhere to long-term to reverse steatosis and improve glycemic control, avoiding the rebound weight gain seen when structured support ends.
• Avoid excessive fructose intake if you are in a calorie surplus: If you are overweight or insulin resistant, avoid fulfilling daily fruit-and-vegetable guidelines primarily with high-fructose fruits (like multiple apples and oranges), as excess fructose is converted directly into liver triglycerides.
• Drink filter coffee and eliminate tobacco: Incorporate coffee (particularly filter coffee) into your routine, as 20–30 years of research link it to lower liver fat and better liver outcomes, and completely avoid tobacco smoking, which independently drives liver fibrosis and liver cancer.
• Discuss newly approved therapeutics if you have MASH with significant fibrosis: If lifestyle changes are insufficient and you have MASH with significant fibrosis, speak with a specialist about conditional FDA/EMA-approved medications like semaglutide (Wegovy) or resmetirom (Rezdiffra) to actively reduce liver scarring alongside diet and exercise.
• Support public health policies that reduce liver disease burden: Advocate for evidence-based structural interventions identified by the EASL-Lancet Commission, including removing VAT/taxes on vegetables, restricting the marketing of alcohol and ultra-processed foods to children, increasing alcohol pricing, and raising minimum legal drinking ages.